No Data
No Data
Verastem Inc. Reports Increased Operating Expenses and Net Loss
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')